VA-VIRTUSTREAM
Virtustream , an enterprise-class cloud company and Dell Technologies business, announced the availability of new start/stop automation for SAP® software landscapes and systems to help enterprises optimize their costs and controls through new self-service tools and step-by-step status updates. The functionality is now available in the Virtustream Enterprise Cloud via the xStream portal .
“Virtustream consistently drives new innovation into its Virtustream Enterprise Cloud platform to meet our demanding requirements and evolving mission-critical needs in the cloud,” says Ettore Tenaglia, Head of Service Operations, Almaviva. “The new automated features and tools help to improve our oversight, management and controls of our SAP environments, allowing us to optimize our processes to save valuable time and costs which can go back into our business.”
Address Compute Costs with Workload Automation
Virtustream’s new automated services reduce the amount of time and manual effort required from an organization’s internal IT team to perform start/stop commands on SAP landscapes and systems. The new tools and features include:
- Strategic Scheduling: Start/stop operations can be scheduled through the Virtustream xStream portal in 30-minute windows on a one-time, on-demand, or recurring basis (daily, weekly or free-form). Additionally, users can set an expiration date for the agentless operation. Creating customized schedules to power virtual machines on or off helps to reduce compute costs. Additionally, automatically shutting down applications when they aren’t being used, such as during weekends and maintenance periods, can further optimize costs.
- Defined Prioritization: Customers can assign each SAP system a set priority, allowing them to stagger the start/stop of their system so they proceed in a defined order, helping to ensure applications run efficiently and correctly.
- Improved Access Control: Only approved administrators or users can access and use the start/stop automation, as dictated by the enterprise’s permission controls within their xStream tenant.
- New Status Updates, Customized Notifications and Action Logs: A new status bar indicates the step-by-step process of each action as it progresses through the SAP system or landscape. Additionally, customized email notifications can be sent to each administrator based on actions (all actions or only scheduled) or by result (all results or failed only). An action log is generated for each system that shows all actions run on a specific SAP system or landscape including who initiated the action, when it was completed, and what actions were taken.
“Automation is key to streamlining IT operations and increasing cloud agility while freeing internal resources to focus on higher-priority projects or initiatives,” says Mike Zolla, Vice President of Cloud Platform Engineering and Delivery, Virtustream. “By extending automation deeper into our mission-critical Virtustream Enterprise Cloud platform, we are helping our enterprise customers increase the economic and business benefits of their SAP applications.”
Backed by Virtustream’s extensive experience migrating, optimizing and managing SAP workloads in the cloud, Virtustream’s new start/stop automation capability is available across all xStream-supported databases. Virtustream’s xStream Management Platform provides a powerful cloud management platform with a single interface across complex, distributed IT environments. xStream delivers economic and business benefits for a broad range of mission-critical enterprise applications in the cloud.
About Virtustream
Virtustream LLC, a Dell Technologies business, is the enterprise-class cloud company that is trusted by organizations worldwide to migrate and run their mission-critical applications in the cloud. For enterprises, service providers, healthcare organizations and government agencies, Virtustream’s xStreamCare professional and managed services, and the xStream® Management Platform and Infrastructure-as-a-Service (IaaS) meet the security, compliance, performance, efficiency, and consumption-based billing requirements of complex production applications in the cloud – whether private, public or hybrid.
Virtustream is a trademark of Virtustream LLC. Other trademarks may be trademarks of their respective owners.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005255/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom